Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 85 years of age.
• People who have been diagnosed with locally advanced extensive-stage small cell lung cancer (ES-SCLC), confirmed by a tissue sample (biopsy).
• People who have been diagnosed with locally advanced or metastatic large cell neuroendocrine carcinoma (LCNEC), confirmed by a tissue sample (biopsy).
• People who are about to begin a standard treatment plan combining platinum-based chemotherapy (cisplatin or carboplatin) with an immunotherapy drug (atezolizumab or durvalumab).
• People who have at least one tumour that can be measured or tracked using standard imaging guidelines (called RECIST 1.1).
• People who have not previously received any systemic (whole-body) treatment for ES-SCLC or LCNEC.
• People whose treating doctor estimates their life expectancy to be at least 3 months.
• People who are willing to attend scheduled follow-up visits and provide blood and/or tissue samples during the study.
• People with a physical functioning level rated 0–2 on the ECOG scale, meaning they are able to carry out at least some daily activities (confirm with trial site).
• People whose blood counts, kidney function, and liver function are considered adequate by their treating doctor.
• People who are willing and able to sign a written consent form and provide blood and tumour tissue samples for research.
• Women of childbearing potential who have a negative pregnancy test at the start of the study and agree to use effective contraception throughout.
• People who do not have medical conditions that would prevent them from safely receiving immunotherapy drugs (such as certain autoimmune diseases requiring immune-suppressing medication).
• People who their treating doctor considers medically fit to receive platinum-based chemotherapy.
• People with brain metastases (cancer that has spread to the brain) may still be eligible if those metastases have already been treated (for example, with surgery or radiotherapy) and have been stable on imaging for at least 4 weeks before joining the trial.
• People with brain metastases who are taking corticosteroid medication may still be eligible if their dose is stable or decreasing and is no more than the equivalent of 10 mg per day of prednisone for at least 2 weeks before joining.
• People who have adequate psychosocial support and the mental capacity to understand and consent to participation.

Who may not be able to join:

• People with untreated or worsening brain metastases that are causing significant neurological symptoms.
• People who have had another active cancer (other than ES-SCLC or LCNEC) within the past 3 years, except for certain treated skin cancers or early-stage cervical cancer that has been treated.
• People who have previously received chemotherapy or immunotherapy for ES-SCLC or LCNEC.
• People with serious ongoing health conditions — such as uncontrolled heart, lung, or autoimmune disease — that could affect their ability to participate or receive treatment.
• People with active infections that require systemic (whole-body) treatment, including tuberculosis, hepatitis B, hepatitis C, or HIV.
• Women who are pregnant or breastfeeding, or women of childbearing potential who are not using effective contraception.
• People who are taking immune-suppressing medications, including high-dose corticosteroids (more than the equivalent of 10 mg per day of prednisone), within 2 weeks before joining the trial.
• People who have had a severe allergic reaction to any component of the planned treatment, including platinum-based chemotherapy or immunotherapy drugs.
• People whose treating doctor estimates their life expectancy to be less than 3 months.
• People who are unable or unwilling to follow the study procedures, including providing samples and attending follow-up visits.

Important: Always verify eligibility with the trial site directly before applying.